Wang S S, FitzSimmons S C, O'Leary L A, Rock M J, Gwinn M L, Khoury M J
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Pediatrics. 2001 Feb;107(2):274-9. doi: 10.1542/peds.107.2.274.
Controlled clinical trial data have suggested that identifying asymptomatic cystic fibrosis (CF) patients through newborn screening improves health outcomes of affected children in the first decade of life. However, it is unclear whether these improvements also include a reduction in risk for bronchial infection, the major determinant of CF morbidity. The authors therefore investigated the association between early CF diagnosis and acquisition of Pseudomonas aeruginosa, the major bronchial pathogen, in the first decade of life.
Longitudinal data on 3625 CF patients diagnosed between 1982 and 1990 and before 36 months of age were ascertained from the National Cystic Fibrosis Patient Registry. We compared P aeruginosa acquisition in the first 10 years of life among 4 groups: EAD (early asymptomatic diagnosis)-<6 weeks, by pre/neonatal screening, genotype, family history (n = 157); ESD (early symptomatic diagnosis) (n = 227); LAD (late asymptomatic diagnosis)-6 weeks to 36 months (n = 161); and LSD (late symptomatic diagnosis) (n = 3080). P aeruginosa acquisition was determined from yearly sputum and/or bronchoscopy cultures. Children whose CF diagnoses followed meconium ileus or whose cultures were obtained only from nasal samples were excluded from the study.
Kaplan Meier analyses for P aeruginosa acquisition were conducted for each diagnostic group. Regression models were used to generate adjusted relative hazards with EAD as the referent group. Relative hazards were 0.9 (95% confidence interval [CI]: 0.7-1.2) for ESD, 0.8 (95% CI: 0.6-1.2) for LAD, and 1.0 (95% CI: 0.7-1.2) for LSD. The risk of acquiring P aeruginosa was therefore not significantly different between children diagnosed early, late, asymptomatically, or symptomatically.
These data suggest that, despite improvements in other health outcomes from newborn screening for CF, early asymptomatic diagnosis of CF does not affect P aeruginosa acquisition.
对照临床试验数据表明,通过新生儿筛查识别无症状囊性纤维化(CF)患者可改善患病儿童出生后第一个十年的健康状况。然而,目前尚不清楚这些改善是否还包括降低支气管感染风险,而支气管感染是CF发病的主要决定因素。因此,作者调查了CF早期诊断与出生后第一个十年中主要支气管病原体铜绿假单胞菌感染之间的关联。
从国家囊性纤维化患者登记处获取了1982年至1990年间诊断出的3625例CF患者的纵向数据,这些患者在36个月龄之前被诊断。我们比较了4组患者出生后前10年中铜绿假单胞菌的感染情况:EAD(早期无症状诊断)-<6周,通过产前/新生儿筛查、基因型、家族史确诊(n = 157);ESD(早期有症状诊断)(n = 227);LAD(晚期无症状诊断)-6周龄至36个月龄(n = 161);LSD(晚期有症状诊断)(n = 3080)。通过每年的痰液和/或支气管镜检查培养来确定铜绿假单胞菌感染情况。CF诊断继发于胎粪性肠梗阻的儿童或仅从鼻拭子样本获取培养物的儿童被排除在研究之外。
对每个诊断组进行了铜绿假单胞菌感染的Kaplan Meier分析。以EAD组作为参照组,使用回归模型生成调整后的相对风险。ESD组的相对风险为0.9(95%置信区间[CI]:0.7 - 1.2),LAD组为0.8(95%CI:为0.6 - 1.2),LSD组为1.0(95%CI:0.7 - 1.2)。因此,早期、晚期、无症状或有症状诊断的儿童获得铜绿假单胞菌的风险没有显著差异。
这些数据表明,尽管CF新生儿筛查在其他健康结局方面有所改善,但CF的早期无症状诊断并不影响铜绿假单胞菌感染。